# (Annual) Work programme 2016 & 2017:

### **EU Reference Laboratory for Classical Swine Fever**

#### I. Contractual duties

The contractual duties of the EURL are specified in Council Directive 2001/89/EC (OJ L 316 of 1.12.2001). On this basis the work programme has been set up.

Page 1/10

# II. Objectives for the period 1<sup>st</sup> of January 2016 to 31<sup>st</sup> of December 2017

| <b>Activities:</b> | <b>Description:</b>   | <b>Objectives:</b>  | <b>Expected Outputs:</b>                      |
|--------------------|---|---------------------|---|
| Activity 1:        | a) Maintenance and enlargement of the Classical                 | Ensure the          | a) 1-10 new virus stocks collected from       |
| Production and     | Swine Fever (CSF) virus collection (virus                       | development and     | possible future CSF outbreaks.                |
| supply of          | bank); propagation of CSF virus strains for                     | use of high quality | b) Collecting data of 1-10 new CSF viruses    |
| reference          | maintenance of existing bank and provision to                   | methods by          | and include information (e.g. sequence        |
| material,          | other laboratories;   | supporting NRLs     | data) in EURL CSF virus database in order     |
| provision of       | b) Updating and maintenance of a World Wide                     | with reference      | to make the information available in a        |
| information        | Web database for CSF virus collection                           | materials and       | "ready to use format" to the NRLs.            |
|                    | (including genome sequence data);                               | information about   | c) 5-20 new reference sera . and 20-80 new    |
|                    | c) Production of new reference materials,                       | these materials for | reference tissue samples from pigs            |
|                    | characterization of respective material by                      | proper validation   | experimentally infected with 4 - 10           |
|                    | comprehensive testing.  | of test methods and | different CSF virus isolates at the EURL      |
|                    | d) Updating and maintenance of a World Wide                     | for coordinating    | facilities (depending on current CSF          |
|                    | Web database for CSF reference sera and tissue                  | and harmonising     | situation and on particular research          |
|                    | samples;  | the applied         | interest). Reference material will be         |
|                    | e) Storage and supply of cell cultures for use in               | laboratory          | obtained from animals infected with           |
|                    | diagnosis and storage and supply of                             | techniques in       | different recombinant CSFV isolates           |
|                    | standardised sera and other reference reagents to               | diagnosis of CSF    | constructed for testing as possible marker    |
|                    | the NRLs upon request for test and reagent                      | throughout the EU   | vaccine candidates.                           |
|                    | standardisation, employed in the Member States,                 | as well as in       | d) Collecting data of 5-20 new sera and 20-80 |
|                    | e.g.  | neighbouring and    | new tissue samples and include data in        |
|                    | <ul> <li>Reference material (sera, monoclonal</li> </ul>        | associated          | EURL CSF sera and tissue database.            |
|                    | antibodies, viruses, clinical specimens, cell                   | countries.          | e) 60-80 supplies of reference reagents to    |
|                    | cultures);  |                     | NRLs and Third Countries upon request         |
|                    | <ul> <li>Serum panels for validation of Antibody</li> </ul>     |                     | f) Agreement on, set up and comparative       |
|                    | ELISA   |                     | testing of a compilation of reference sera    |
|                    | <ul> <li>Panels for validation of PCR tests;</li> </ul>         |                     | for internationally comparable ELISA          |
|                    | <ul> <li>Highly virulent CSF virus for direct use in</li> </ul> |                     | control (effective comparability of batch     |
|                    | (vaccination) challenge experiments;                            |                     | control in the different NRLs carried out     |
|                    | <ul> <li>Provision of photographs or slideshows of</li> </ul>   |                     | for registration of tests in the different    |

Page 2/10 Date: 23/09/15

| <b>Activities:</b> | Description:  | <b>Objectives:</b> | <b>Expected Outputs:</b>                      |
|--------------------|---|--------------------|---|
|                    | CSF virus infected pigs for teaching                |                    | member states; evaluation of new tests        |
|                    | purposes.   |                    | etc.).  |
|                    | f) Discussion of the need and implementation of     |                    | g) Increase biological safety in exchange of  |
|                    | an international standardized and quantifiable      |                    | sera between laboratories by application of   |
|                    | reference serum panel for ELISA batch control.      |                    | procedures and protocols for effective        |
|                    | Organization of a Meeting at the EURL in            |                    | reduction of infectious virus in porcine      |
|                    | Hannover with selected NRL experts for              |                    | serum (rendering the material non-            |
|                    | information exchange, determination of the          |                    | infectious) without affecting test results in |
|                    | requirements and coordination of the project.       |                    | diagnostic methods applied for serological    |
|                    | g) Establishment of procedures for inactivation of  |                    | testing).                                     |
|                    | CSFV positive sera to be supplied to the NRLs       |                    | h) Availability thorough information about    |
|                    | for serological investigations.                     |                    | current, state-of-the-art diagnostic          |
|                    | h) Updating the Technical part of EU Diagnostic     |                    | techniques with regard to the detection of    |
|                    | Manual for Diagnosis of Classical Swine Fever       |                    | Classical Swine Fever.                        |
|                    | (CSF)   |                    | i) Confirmation of laboratory diagnosis.      |
|                    | i) Diagnostic laboratory testing of sample material |                    | Number of tests is depending on the           |
|                    | for confirmation/ exclusion or differential         |                    | respective outbreak situation in the EU and   |
|                    | diagnosis when Classical Swine Fever is             |                    | neighbouring countries.                       |
|                    | suspected;  |                    |   |

| <b>Activities:</b>                                  | <b>Description:</b>   | <b>Objectives:</b>  | <b>Expected Outputs:</b>   |
|---|---|---|--|
| Activity 2: Inter-laboratory comparison test (ILCT) | <ul> <li>Organising comparative tests of diagnostic procedures at Community level on an annual basis.</li> <li>Production of reference material for ILCT panel.</li> <li>Set up of CSF ILCT panel in cooperation with and according to the advice of the scientific advisory board;</li> <li>Preparation, validation of CSF ILCT panel;</li> <li>Notification of participating laboratories, packaging and shipment of CSF ILCT panel.</li> <li>Collection of results and evaluation of ILCT results.</li> <li>Communicating results of ILCT to participating laboratories and EU Commission (DG SANCO) by provision of a compiled report and by presenting the data in the frame of the Workshop/ Annual Meeting of Classical Swine Fever Reference Laboratories.</li> <li>Follow-up of non-conformities of ILCT (by e.g. email communication as well as direct interaction by laboratory visits or training sessions in order to identify and eliminate the source of non-conformity).</li> </ul> | To maintain an appropriate level of proficiency testing ensuring efficiency of control analysis methods, by performing control of NRLs in diagnostic techniques for the detection of CSF (European Union laboratories and third countries). Harmonisation of methods applied in NRLs. | Organization of new ILCTs (2016 & 2017) and follow-up of "previous" ILCTs (2015 & 2016) Each ILCT panel will contain about 15-25 samples that can be tested in 8 different diagnostic tests.  • Each year 28 panels (to EU NRLs) and about 10 - 20 panels to other laboratories (e.g. EU candidate and pre-accession countries, associated countries as well as strategically important countries).  • High level of successful completion of testing by the NRLs after first round of testing, for laboratories with major discrepancies in the first round of diagnostic testing considerable improvement after application of follow-up measures determined by second round of testing. |

| <b>Activities:</b> | Description:                                       | <b>Objectives:</b>   | <b>Expected Outputs:</b>                       |
|--------------------|--|----------------------|--|
| Activity 3:        | Molecular and biological characterisation of CSF   | Facilitating the     | a) Performance of 1-2 animal experiments with  |
| Characterization   | virus isolates and novel vaccine candidates by the | understanding of     | CSF field viruses and genetically engineered   |
| of virus isolates  | most up-to-date methods available.                 | epizootiology of     | viruses at the EURL facilities.                |
|                    | a) Animal experiments for studying virulence       | CSF.                 | b) Characterization of 1-10 new viruses        |
|                    | and pathogenesis of recent CSF virus isolates;     | Ensure the           | collected from future CSF outbreaks in the     |
|                    | and to characterize new candidates for live        | development and use  | EU and Third Countries (depending on           |
|                    | attenuated marker vaccines.                        | of high quality      | outbreak situation) and distribution of the    |
|                    | b) Sequence analysis of recent CSF virus isolates  | analytical methods   | generated information by the Classical Swine   |
|                    | from primary outbreaks of CSF in the EU and        | within the           | Fever database and publications.               |
|                    | Third Countries (upon request) and evaluation      | laboratories by      | c) Increasing the number of complete CSF viral |
|                    | of data from Member States on molecular            | improving methods    | genome sequences available for phylogenetic    |
|                    | epidemiology of CSF                                | applied in CSF virus | analysis.                                      |
|                    | c) Sequencing of complete CSF virus genomes        | phylogeny.           |  |
|                    | in order to fill in gaps of knowledge;             |                      |  |
|                    | d) Optimization of CSF virus sequence analysis     |                      |  |
|                    | in case of outbreaks (e.g. implementation of       |                      |  |
|                    | workflows/expertise for determination of           |                      |  |
|                    | complete CSFV genomes).                            |                      |  |
|                    | e) Publication, provision and transfer of new      |                      |  |
|                    | methods to NRLs;                                   |                      |  |

| <b>Activities:</b>                                 | <b>Description:</b>   | <b>Objectives:</b>   | <b>Expected Outputs:</b>  |
|--|---|--|---|
| Activity 4: Gathering of information and expertise | <ul> <li>a) Retaining expertise on the virus causing CSF and other relevant viruses (e.g. ruminant pestiviruses and African Swine Fever Virus to enable rapid differential diagnosis); Keeping abreast of new developments regarding CSF surveillance, epizootiology and CSF prevention throughout the world and of developments regarding preparation and use of products of veterinary immunology applied in order to control and eradicate CSF;</li> <li>b) Maintaining and extending networking activities with laboratory experts on CSF diagnosis and scientists working in the field of CSF virus;</li> <li>c) Collecting and collating data and information on the methods of diagnosis and the results of tests carried out;</li> <li>• Collection of the country report data on CSF diagnostic activities via a web based template;</li> <li>• Collection of wild boar data of the countries situation via a web based template and in parallel generation of the wild boar report directly via the "CSF in wild boar" surveillance database;</li> <li>• Editing of data and reporting to NRLs and EC.</li> </ul> | Ensure the availability of scientific and technical assistance by the EURL continuous qualification of staff, which is available for emergency situations occurring within the EU in order to assist during outbreaks/crisis situations.  Assistance of the Commission, EFSA, ECDC and EMA in case of specific requests.  Contribution to risk assessment and reviews of manuals or codes. | <ul> <li>a) 5-12 participations in relevant congresses and meetings (2016- 2017).</li> <li>b) On-going reciprocal exchange of information with competent institutions, laboratories and universities in the EU and Third Countries</li> <li>c) Collection of CSF country report and CSF Wild Boar report data and provision of the edited data to NRLs and DG Sanco.</li> <li>d) Timely and adequate answering to all requests for assistance raised by the NRLs or other parties.</li> </ul> |

| Activities:   | <b>Description:</b>   | <b>Objectives:</b>   | <b>Expected Outputs:</b>  |
|---|---|--|---|
| Activity 5: "CSF/ASF Wild Boar surveillance database"             | <ul> <li>Maintenance of CSF/ASF in wild boar surveillance database (subcontracting with Friedrich-Loeffler-Institute, Greifswald – Insel Riems, Germany)</li> <li>Telephone and e-mail assistance through a support employee;</li> <li>Technical maintenance of the CSF/ASF in wild boar surveillance database;</li> <li>Support of Latvia, Lithuania, Estonia, Austria and Poland through individually customized training sessions and workshops in each country;</li> <li>Integration of a new "Quick Map Viewer"</li> </ul> | Risk assessment: Gathering and processing of data for improving the information available on CSF/ASF in wild boar situation in the EU and neighbouring countries.  | <ul> <li>Maintaining CSF/ASF in wild boar surveillance database.</li> <li>Individually customized training sessions and workshops (5x) held in countries interested in joining the database.</li> </ul> |
| Activity 6: Provision of training in diagnosis of CSF at the EURL | Provision of individual trainings in laboratory diagnosis for CSF (e.g. if there is new personnel at an NRL, if re-training of experts is needed or in case there is need for assistance if new techniques are to be established at an NRL).  (Upon request of the European Commission or TAIEX, the training offer may also include the training of experts from non-EU countries).  | Ensure the development and use of high quality analytical methods by training sessions carried out for improving the performance level of NRLs (e.g. as a follow-up of poor ILCT results) in diagnostic testing of CSF. Harmonisation of methods applied in different laboratories. Help with establishing new diagnostic techniques in NRLs for improvement of diagnostic standard. Increasing the number of trained personnel available for emergency situations occurring within the Community. | Training in state-of-the-art of analytical methods for the detection of Classical swine fever of 4-6 visitors for a time period of 1-2 weeks training each.   |

Page 7/10 Date: 23/09/15

| Activities:   | <b>Description:</b>   | Objectives:   | <b>Expected Outputs:</b>   |
|---|---|---|--|
| Activity 7: Organization of an "Workshop on CSF/ ASF diagnosis and control" for National Reference Laboratories (in cooperation with DG Sanco and the EURL for ASF) | <ul> <li>Preparation and organization of Workshop</li> <li>Compilation of programme and working documents for CSF part;</li> <li>Scientific contribution: presentation of ILCT results, EURL activities and latest research activities;</li> <li>Collection and editing of material for a report on Workshop;</li> <li>Preparation of Workshop report;</li> <li>Providing Workshop's presentations for download on the website of the EURL in an access-restricted area.</li> </ul> | Dissemination of information on newly developed analytical methods/ news on reference methods in laboratory diagnosis of CSF to the NRL experts for ensuring the use of high quality analytical methods among the NRLs, with a view to harmonize the applied diagnostic techniques. Exchange of information on current CSF situation in Member States and in neighbouring countries of the EU. Platform for presenting news with regard to epidemiology and control of CSF and updates on relevant research topics. | <ul> <li>Organization of a joint Workshop on CSF and ASF diagnosis and control for 2016 taking place in Hannover (EURL for CSF is host of the meeting) and for 2017 in Valdeolmos (hosted by the EURL for ASF).</li> <li>Harmonization and thus application of state-of-the-art analytical methods within EU and associated countries.</li> <li>Exchange of relevant practical experience and findings regarding laboratory diagnosis and control of CSF for identifying future requirements for the applied diagnostic techniques and determining the possibilities for further optimization.</li> <li>Participation of representatives from 29 EU NRLs and in addition of representatives from strategically important non-EU laboratories in the Workshop.</li> </ul> |
| Activity 8: Missions and permanent training of staff  | <ul> <li>a) Provision of trained personnel for missions to National Swine Fever Laboratories/ Member States asking for assistance. Provision of trained personnel for missions on demand of DG SANCO;</li> <li>b) Permanent training of staff to keep abreast of new developments, including the attendance of</li> </ul>   | Ensure the availability of scientific and technical assistance to the NRLs and other parties by supporting the professional development of personnel, and sending trained personnel whenever necessary (e.g. in case of emergency situations occurring within the   | <ul> <li>a) 1-4 visits to NRLs for training sessions and/ or inspection visits for determination of laboratory capacities regarding CSF diagnosis (number of visits is depending on CSF situation in the EU and e.g. on performance of NRLs in ILCT testing).</li> <li>b) Participation in international meetings and conferences, attending of seminars on virology.</li> </ul>   |

Page 8/10 Date: 23/09/15

| <b>Activities:</b>  | <b>Description:</b>   | Objectives:  | <b>Expected Outputs:</b>  |
|---|---|--|---|
|   | international meetings and conferences;   | Community).  | -   |
| Activity 9: Projects and activities related to improved CSF virus diagnosis and control | <ul> <li>Identification and characterization of new pestiviruses Testing of experimentally derived sera obtained after application of novel genetically engineered CSFV marker vaccines in combination with a recently developed Erns double-antigen ELISA as the serological DIVA assay.</li> <li>Preparation and publication of articles and reports associated with above work, attendance of international meetings and conferences.</li> </ul> | Performing research activities and whenever possible coordinate research activities directed towards an improved control of CSF. | <ul> <li>Enhancing knowledge on heterogeneity of pestiviruses in order to improve differentiation between CSFV and other porcine as well as ruminant pestiviruses;</li> <li>To gather information about performance of a novel Erns ELISA for application as a putative DIVA assay in combination with several prototypes of marker vaccines differing to the CP7-E2alf marker vaccine</li> <li>Mutual exchange of information with competent laboratories /authorities in the EU and in Third Countries.</li> <li>Contribution to scientific conferences, e.g. presentations of research results (speaker, posters).</li> <li>Publications in peer-reviewed journals.</li> </ul> |

It is understood that the above mentioned objectives are not exclusive to other work of more immediate priority which may arise during the given period.

Page 9/10 Date: 23/09/15

### **ANNEX**

### Projects and related research activities funded by other sources

- Project "Mechanisms and biological significance of genetic variability of RNA viruses" (BE 2333/2-2) funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Council);
- Project "Identification and characterization of novel viruses originating from farm animals". Part of the activities of the DZIF ("Deutsches Zentrum für Infektionsforschung"). Funded by the Bundesministerium für Bildung und Forschung.
- Member of the *Flaviviridae* Study group of the International Committee on Taxonomy of Viruses, ICTV (Prof. Paul Becher);
- Participation in international research projects and networks, e.g. European Research Group (former "EPIZONE");

Page 10/10 Date: 23/09/15